Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Zemimet® SR (Gemigliptin/Metformin) vs Co-administration of Zemiglo and Glucophage XR
NCT04050098Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoint: Rate and extent of absorption (Bioequivalence) at 48 hours. Status: unknown.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04050098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050098.